Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXP900 and Osimertinib in Advanced EGFR-Mutated NSCLC
NCT07315113Phase 1Recruiting
- Sponsor
- Nuvectis Pharma, Inc.
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NXP900 in non-small cell lung cancer (NSCLC), sponsored by Nuvectis Pharma, Inc. Primary endpoints: Adverse Events at 30 days, Objective Response Rate at 12 months and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
NXP900
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07315113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07315113.